Ulcerative colitis (UC)

Ulcerative Colitis (UC) is a chronic inflammatory condition confined primarily to the colon and rectum, forming part of a group of conditions known as Inflammatory Bowel Diseases (IBD). It is characterized by the inflammation and continuous ulceration of the mucosal layer of the colon, which distinguishes it from Crohn's Disease, another type of IBD that can affect any part of the gastrointestinal tract and involves deeper layers of the bowel wall. The exact etiology of UC remains unclear, but it is understood to be a complex interplay of genetic predisposition, environmental factors, immune system malfunctions, and alterations in the gut microbiome.

Clinically, UC presents with symptoms including persistent diarrhea, rectal bleeding, abdominal pain, and urgency in bowel movements. The severity of these symptoms can range from mild to debilitating, often with periods of remission and exacerbation. Complications may include severe bleeding, perforated colon, and an increased risk of colon cancer, particularly in patients with extensive and long-standing inflammation.

Diagnostically, UC is confirmed through a combination of endoscopic examination of the colon, histopathological analysis of colonic biopsies, and imaging studies. Management strategies for UC aim at inducing and maintaining remission, and involve the use of medications such as aminosalicylates, corticosteroids, immunomodulators, and biologics targeting specific pathways of the immune system. In severe cases, surgical interventions such as colectomy may be necessary. Additionally, lifestyle modifications and nutritional support play a crucial role in managing symptoms and improving quality of life. Ongoing research continues to explore the pathogenesis of UC, seeking to develop more targeted and effective therapies and to understand the long-term impacts of the disease.

References:

Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT. Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol. 2015 Feb 15;6(1):13-22. doi: 10.4291/wjgp.v6.i1.13. PMID: 25685607; PMCID: PMC4325297. [L]

Antoniussen CS, Rasmussen HH, Holst M, Lauridsen C. Reducing Disease Activity of Inflammatory Bowel Disease by Consumption of Plant-Based Foods and Nutrients. Front Nutr. 2021 Dec 9;8:733433. doi: 10.3389/fnut.2021.733433. PMID: 34957174; PMCID: PMC8696360. [L]

Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019 Jul;94(7):1357-1373. doi: 10.1016/j.mayocp.2019.01.018. Erratum in: Mayo Clin Proc. 2019 Oct;94(10):2149. PMID: 31272578. [L]

Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019 Dec;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004. Epub 2019 Mar 2. PMID: 30837080. [L]

Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. Nat Rev Dis Primers. 2020 Sep 10;6(1):74. doi: 10.1038/s41572-020-0205-x. PMID: 32913180. [L]

Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA. 2023 Sep 12;330(10):951-965. doi: 10.1001/jama.2023.15389. PMID: 37698559. [L]

Lynch WD, Hsu R. Ulcerative Colitis. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29083748. [L]

Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014 Apr-May;13(4-5):463-6. doi: 10.1016/j.autrev.2014.01.028. Epub 2014 Jan 11. PMID: 24424198. [L]

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152. PMID: 30840605. [L]

Learn more

Ulcerative colitis (UC)

Biomarkers related to this condition:

ANCA SCREEN / Lab ANCA Interpretation

Perinuclear (P-ANCA)

Streptococcus salivarius

All Health Conditions